Document is current

Any future updates will be listed below

673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

Crossref DOI link: https://doi.org/10.1136/jitc-2023-SITC2023.0673

Published Online: 2023-11-02

Published Print: 2023-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark